Cepheid (Sunnyvale, CA) received a notice of grant award from the National Institute of Allergy and Infectious Diseases to develop new ten-color detection technology for use in its GeneXpert System. The $7.5 million grant will be awarded to Cepheid and the University of Medicine and Dentistry of New Jersey during the planned five-year program. When coupled with Cepheid's virtual array technology, the new ten-color system will have the potential to simultaneously detect up to 100 different targets per sample. Cepheid's current GeneXpert System is capable of six-color detection, with the potential for up to 60 different targets per sample. The new ten-color technology is expected to deliver more cost-effective infectious disease panel testing applications by increasing the total number of diagnostic results per sample. The technology will also enable the development of new, comprehensive antimicrobial resistance and oncology tests. Building upon the success of Cepheid's six-color Xpert MTB/RIF test, clinical utility of the ten-color system will be demonstrated through the development of a new assay for multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis. Future GeneXpert-based tests, which apply the ten-color technology, are expected to follow.